RT Journal Article
SR Electronic
T1 Quantifying the impact of SARS-CoV-2 temporal vaccination trends and disparities on disease control
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.23.23286326
DO 10.1101/2023.02.23.23286326
A1 Larsen, Sophie L.
A1 Shin, Ikgyu
A1 Joseph, Jefrin
A1 West, Haylee
A1 Anorga, Rafael
A1 Mena, Gonzalo E.
A1 Mahmud, Ayesha S.
A1 Martinez, Pamela P.
YR 2023
UL http://medrxiv.org/content/early/2023/02/26/2023.02.23.23286326.abstract
AB SARS-CoV-2 vaccines were developed and distributed during a global crisis at unprecedented speed. Still, little is known about trends in vaccine uptake over time, their association with socioeconomic inequality, and the impact of these temporal trends on disease control. By analyzing data from dozens of countries, we examined vaccination rates across high and low socioeconomic (SES) groups, showing that socioeconomic disparities in the fraction of the population vaccinated exist at both national and sub-national levels. We also identified two distinct vaccination trends: one characterized by rapid initial roll-out, quickly reaching a plateau; and another trend that is sigmoidal and slow to begin. Informed by these patterns, we implemented an SES-stratified mechanistic model, finding profound differences across the two vaccination types in the burden of infections and deaths. The timing of initial roll-out has a more significant effect on transmission and deaths than the eventual level of coverage or the degree of SES disparity. Surprisingly, the speed of the roll-out is not associated with wealth inequality or GDP per capita of countries. While socioeconomic disparity should be addressed, accelerating the initial roll-out for all groups is a broadly accessible intervention and has the potential to minimize the burden of infections and deaths across socioeconomic groups.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data was available to the public before the initiation of the study. Sources can be found in the supplementary materials.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data collected in this project are publicly available, with sources listed in the supplementary materials. All code and data to reproduce the figures in the main text will be provided upon acceptance.